AMENDMENT NO. 1 TO THE NOVATION AGREEMENTNovation Agreement • May 9th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 (the “Amendment”), effective as of April 25, 2024 (the “Amendment Effective Date”) to the Novation Agreement effective as of July 21, 2023 and executed on September 19, 2023 (the “Novation Agreement”) is entered into by and among (i) Paragon Therapeutics, Inc., a Delaware corporation with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (the “Transferor”), (ii) Spyre Therapeutics, Inc. (f/k/a Aeglea BioTherapeutics, Inc.), a Delaware corporation with an office at 221 Crescent Street Building 23, Suite 105, Waltham, MA 02453 (“Spyre”), and (iii) WuXi Biologics (Hong Kong) Limited, a Hong Kong corporation with its registered address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (the “Counterparty”).
